BR0112721A - Use of estramustine phosphate in the treatment of bone metastasis - Google Patents

Use of estramustine phosphate in the treatment of bone metastasis

Info

Publication number
BR0112721A
BR0112721A BR0112721-7A BR0112721A BR0112721A BR 0112721 A BR0112721 A BR 0112721A BR 0112721 A BR0112721 A BR 0112721A BR 0112721 A BR0112721 A BR 0112721A
Authority
BR
Brazil
Prior art keywords
treatment
estramustine phosphate
bone metastasis
bone
phosphate
Prior art date
Application number
BR0112721-7A
Other languages
Portuguese (pt)
Inventor
Beryl Asp
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0112721A publication Critical patent/BR0112721A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE FOSFATO DE ESTRAMUSTINA NO TRATAMENTO DE METASTASE óSSEA". O fosfato de estramustina é mostrado para agir como um inibidor de reabsorção óssea e pode ser usado assim, para tratar, prevenir ou aliviar os sintomas de metástase óssea que surgem devido a dita reabsorção óssea."USE OF STRAMUSTIN PHOSPHATE IN TREATMENT OF BONE METASTASE". Estramustine phosphate is shown to act as a bone resorption inhibitor and can thus be used to treat, prevent or alleviate the symptoms of bone metastasis arising from such bone resorption.

BR0112721-7A 2000-07-25 2001-07-23 Use of estramustine phosphate in the treatment of bone metastasis BR0112721A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,540 US6436913B1 (en) 2000-07-25 2000-07-25 Use of estramustine phosphate in the treatment of bone metastasis
PCT/US2001/023179 WO2002007719A1 (en) 2000-07-25 2001-07-23 Use of estramustine phosphate in the treatment of bone metastasis

Publications (1)

Publication Number Publication Date
BR0112721A true BR0112721A (en) 2003-06-24

Family

ID=24506563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112721-7A BR0112721A (en) 2000-07-25 2001-07-23 Use of estramustine phosphate in the treatment of bone metastasis

Country Status (13)

Country Link
US (1) US6436913B1 (en)
EP (1) EP1328264A4 (en)
JP (1) JP2004504346A (en)
KR (1) KR20030019612A (en)
CN (1) CN1446086A (en)
AR (1) AR029958A1 (en)
AU (1) AU2001277115A1 (en)
BR (1) BR0112721A (en)
CA (1) CA2412392A1 (en)
MX (1) MXPA03000313A (en)
PE (1) PE20020301A1 (en)
WO (1) WO2002007719A1 (en)
ZA (1) ZA200210285B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
IT1318689B1 (en) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa USE OF ARGININE IN THE PREPARATION OF A MEDICATION FOR THE PREPARATION AND TREATMENT OF THE SIDE EFFECTS ASSOCIATED WITH
US20040014729A1 (en) * 2001-07-23 2004-01-22 Beryl Asp Use of estramustine phosphate in the treatment of bone metastasis
EP1644388A2 (en) * 2003-06-27 2006-04-12 ODANI, Akira Bisphosphonate complexes
JP2005055881A (en) * 2003-07-22 2005-03-03 Fuji Photo Film Co Ltd Drawing method and drawing apparatus
CN100340296C (en) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 Anticarcinogenic internal implant agent
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
AU750010B2 (en) * 1998-03-27 2002-07-11 Pharmacia & Upjohn Company Methods to potentiate intravenous estramustine phosphate
IL146872A0 (en) * 1999-06-03 2002-08-14 Methods and compositions for modulating cell proliferation and cell death

Also Published As

Publication number Publication date
CA2412392A1 (en) 2002-01-31
CN1446086A (en) 2003-10-01
US6436913B1 (en) 2002-08-20
PE20020301A1 (en) 2002-04-07
ZA200210285B (en) 2003-12-19
EP1328264A1 (en) 2003-07-23
AR029958A1 (en) 2003-07-23
KR20030019612A (en) 2003-03-06
JP2004504346A (en) 2004-02-12
EP1328264A4 (en) 2004-01-28
MXPA03000313A (en) 2003-06-06
AU2001277115A1 (en) 2002-02-05
WO2002007719A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
BR0208192A (en) Spirotricylic derivatives and their use as phosphodiesterase-7 inhibitors.
BR0212924A (en) Glycogen synthase kinase-3 (gsk-3) inhibitors for the treatment of glaucoma
ATE346039T1 (en) SULFONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES
BR9708632A (en) Calcilic compounds
NO307027B1 (en) Use of riluzole in the treatment of neurological lesions related to traumatic injuries
BR0114913A (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AR035987A1 (en) USE OF A PDE 4 INHIBITING COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND THE MEDICINAL PRODUCT TO TREAT ASTHMA INDUCED BY EXERCISE
KR970706002A (en) Use of Aromatase Inhibitors in the Preparation of a Drug for Relative Androgen Deficiency in Men in the Preparation of a Medicament for the Treatment of Relative Androgen Deficiency in Male
BR0014041A (en) Use of csaids in rhinovirus infection
BR0110506A (en) Use of il-18 inhibitors for the treatment and / or prevention of atherosclerosis.
BR9509006A (en) Composition for topical application to the skin pharmaceutical composition use of a cholesterol synthesis inhibitor and process for the treatment of mitigation or prevention of skin disorders
BRPI0406796A (en) Methods for treating benign prostatic hypertrophy, reducing a symptom associated with it, reducing prostate size in a human subject, and for bhp prophylaxis, oral unit dose pharmaceutical composition, and use of lonidamine or a lonidamine analogue
BR0010531A (en) Compositions and uses of et743 for cancer treatment
BR0210013A (en) Pyrenzepine Ophthalmic Gel
BR9807523A (en) Quinoxalins in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS.
BR0112721A (en) Use of estramustine phosphate in the treatment of bone metastasis
BR0112547A (en) Process for finding compounds that are suitable for obesity treatment and / or prophylaxis
BRPI0408491A (en) treatment of alzheimer's disease
DK1463735T3 (en) Imidazo-2,1-B -1,3,4-thiadiazole sulfonamides
BR0013625A (en) Composition for use in the treatment of hepatocellular carcinoma
FI20000635A0 (en) Use of COMT inhibitors as an analgesic
BR9903981A (en) Methylcyclotetradec-5-en-1-ones
BR9908716A (en) Treatment of sexual dysfunction in certain groups of patients
BR0109770A (en) Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease
ID26965A (en) MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2021 DE 29/09/2009.